47
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Can insulin signaling pathways be targeted to transport Aβ out of the brain?

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Although the causal role of Amyloid-β (Aβ) in Alzheimer’s disease (AD) is unclear, it is still reasonable to expect that lowering concentrations of Aβ in the brain may decrease the risk of developing the neurocognitive symptoms of the disease. Brain capillary endothelial cells forming the blood-brain barrier (BBB) express transporters regulating the efflux of Aβ out of the cerebral tissue. Age-related BBB dysfunctions, that have been identified in AD patients, might impair Aβ clearance from the brain. Thus, targeting BBB outward transport systems has been suggested as a way to stimulate the clearance of Aβ from the brain. Recent data indicate that the increase in soluble brain Aβ and behavioral impairments in 3×Tg-AD mice generated by months of intake of a high-fat diet can be acutely reversed by the administration of a single dose of insulin. A concomitant increase in plasma Aβ suggests that clearance from the brain through the BBB is a likely mechanism for this rapid effect of insulin. Here, we review how BBB insulin response pathways could be stimulated to decrease brain Aβ concentrations and improve cognitive performance, at least on the short term.

          Related collections

          Most cited references130

          • Record: found
          • Abstract: found
          • Article: not found

          APP processing and synaptic function.

          A large body of evidence has implicated Abeta peptides and other derivatives of the amyloid precursor protein (APP) as central to the pathogenesis of Alzheimer's disease (AD). However, the functional relationship of APP and its proteolytic derivatives to neuronal electrophysiology is not known. Here, we show that neuronal activity modulates the formation and secretion of Abeta peptides in hippocampal slice neurons that overexpress APP. In turn, Abeta selectively depresses excitatory synaptic transmission onto neurons that overexpress APP, as well as nearby neurons that do not. This depression depends on NMDA-R activity and can be reversed by blockade of neuronal activity. Synaptic depression from excessive Abeta could contribute to cognitive decline during early AD. In addition, we propose that activity-dependent modulation of endogenous Abeta production may normally participate in a negative feedback that could keep neuronal hyperactivity in check. Disruption of this feedback system could contribute to disease progression in AD.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain.

            Amyloid-beta peptide (Abeta) interacts with the vasculature to influence Abeta levels in the brain and cerebral blood flow, providing a means of amplifying the Abeta-induced cellular stress underlying neuronal dysfunction and dementia. Systemic Abeta infusion and studies in genetically manipulated mice show that Abeta interaction with receptor for advanced glycation end products (RAGE)-bearing cells in the vessel wall results in transport of Abeta across the blood-brain barrier (BBB) and expression of proinflammatory cytokines and endothelin-1 (ET-1), the latter mediating Abeta-induced vasoconstriction. Inhibition of RAGE-ligand interaction suppresses accumulation of Abeta in brain parenchyma in a mouse transgenic model. These findings suggest that vascular RAGE is a target for inhibiting pathogenic consequences of Abeta-vascular interactions, including development of cerebral amyloidosis.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The many faces of insulin-like peptide signalling in the brain.

              Central and peripheral insulin-like peptides (ILPs), which include insulin, insulin-like growth factor 1 (IGF1) and IGF2, exert many effects in the brain. Through their actions on brain growth and differentiation, ILPs contribute to building circuitries that subserve metabolic and behavioural adaptation to internal and external cues of energy availability. In the adult brain each ILP has distinct effects, but together their actions ultimately regulate energy homeostasis - they affect nutrient sensing and regulate neuronal plasticity to modulate adaptive behaviours involved in food seeking, including high-level cognitive operations such as spatial memory. In essence, the multifaceted activity of ILPs in the brain may be viewed as a system organization involved in the control of energy allocation.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Aging Neurosci
                Front Aging Neurosci
                Front. Aging Neurosci.
                Frontiers in Aging Neuroscience
                Frontiers Media S.A.
                1663-4365
                16 June 2015
                2015
                : 7
                : 114
                Affiliations
                [1] 1Faculté de Pharmacie, Université Laval Quebec, QC, Canada
                [2] 2Axe Neurosciences, Centre de Recherche du Centre Hospitalier de l’Université Laval (CHUL) Québec, QC, Canada
                [3] 3Institut des Nutraceutiques et des Aliments Fonctionnels, Université Laval Québec, QC, Canada
                Author notes

                Edited by: Roxana Octavia Carare, University of Southampton, UK

                Reviewed by: Othman Ghribi, University of North Dakota School of Medicine and Health Sciences, USA; Jonathan Peter Little, University of British Columbia Okanagan, Canada

                *Correspondence: Frédéric Calon, Centre Hospitalier de l’Université Laval (CHUL) Research Center, Room T2-67, 2705 Laurier Blvd., Quebec, QC G1V 4G2, Canada frederic.calon@ 123456crchul.ulaval.ca
                Article
                10.3389/fnagi.2015.00114
                4468380
                26136681
                3e5f7f1e-642b-4545-bf38-74f8a2b77c74
                Copyright © 2015 Vandal, Bourassa and Calon.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 14 February 2015
                : 29 May 2015
                Page count
                Figures: 1, Tables: 0, Equations: 0, References: 184, Pages: 11, Words: 11062
                Categories
                Neuroscience
                Review

                Neurosciences
                insulin,blood-brain barrier,amyloid beta-peptides,alzheimer’s disease,brain capillary endothelial cells,insulin therapy,insulin transporter

                Comments

                Comment on this article